Publication | Closed Access

Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy

Advanced Non-squamous NsclcCost-effectiveness AnalysisClinical EffectivenessBevacizumab Versus PemetrexedOutcomes ResearchPharmacoeconomicsPharmacotherapyCost EffectivenessDrug TrialMedicineEpidemiology